What is the current valuation of the Europe Pharmaceutical Market?

As of 2024, the Europe Pharmaceutical Market was valued at 465.5 USD Billion. Read More

What is the projected market valuation for the Europe Pharmaceutical Market in 2035?

The market is projected to reach a valuation of 659.18 USD Billion by 2035. Read More

What is the expected CAGR for the Europe Pharmaceutical Market during the forecast period 2025 - 2035?

The expected CAGR for the Europe Pharmaceutical Market during the forecast period 2025 - 2035 is 3.21%. Read More

Which therapeutic area is expected to generate the highest revenue in the Europe Pharmaceutical Market?

Oncology is anticipated to generate the highest revenue, with projections ranging from 120.0 to 180.0 USD Billion. Read More

How do prescription drugs compare to over-the-counter drugs in terms of market size?

In 2024, prescription drugs were valued at 186.2 to 265.0 USD Billion, significantly higher than over-the-counter drugs, which were valued at 45.5 to 65.0 USD Billion. Read More

What are the projected revenues for the online pharmacy distribution channel by 2035?

The online pharmacy distribution channel is projected to generate revenues between 30.0 and 70.0 USD Billion by 2035. Read More

Which companies are considered key players in the Europe Pharmaceutical Market?

Key players in the market include Roche, Novartis, Sanofi, Bayer, GlaxoSmithKline, AstraZeneca, Merck KGaA, Boehringer Ingelheim, AbbVie, and Pfizer. Read More

What is the expected revenue range for biologics in the Europe Pharmaceutical Market?

Biologics are expected to generate revenues between 85.0 and 120.0 USD Billion during the forecast period. Read More

How does the market size for hospitals compare to that of clinics in 2024?

In 2024, the market size for hospitals was projected at 150.0 to 210.0 USD Billion, whereas clinics were projected at 80.0 to 120.0 USD Billion. Read More

What is the anticipated revenue range for injectable formulations by 2035?

Injectable formulations are anticipated to generate revenues between 150.0 and 220.0 USD Billion by 2035. Read More

Sweden Pharmaceutical Market

ID: MRFR/Pharma/20196-HCR

128 Pages

Nidhi Mandole

Last Updated: April 06, 2026

Sweden Pharmaceutical Market Research Report Information By Therapeutic Class (Alimentary Tract and Metabolism, Blood and Blood Forming Organs, Cardiovascular System, Dermatological Drugs, Genitourinary System, Reproductive Hormones, Systemic Hormonal Preparations, Immunomodulating Agents, Musculoskeletal System, Nervous System, Ant parasitic Products, Insecticides and Repellents, Respiratory System, Sensory Organs, Various ATC Structures), By Drug Type (Branded, Generic) By Prescription Type (Prescription Drugs (Rx), OTC Drugs) – Sweden’s Market Forecast Till 2035

Sweden Pharmaceutical Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Therapeutic Area (USD Billion)
  1. 4.1.1 Cardiovascular
  2. 4.1.2 Oncology
  3. 4.1.3 Neurology
  4. 4.1.4 Diabetes
  5. 4.1.5 Infectious Disease
2. 4.2 Healthcare, BY Drug Type (USD Billion)
  1. 4.2.1 Prescription Drug
  2. 4.2.2 Over-the-Counter Drug
  3. 4.2.3 Biologics
  4. 4.2.4 Generics
  5. 4.2.5 Orphan Drug
3. 4.3 Healthcare, BY Distribution Channel (USD Billion)
  1. 4.3.1 Hospital Pharmacy
  2. 4.3.2 Retail Pharmacy
  3. 4.3.3 Online Pharmacy
  4. 4.3.4 Specialty Pharmacy
  5. 4.3.5 Wholesalers
4. 4.4 Healthcare, BY Formulation Type (USD Billion)
  1. 4.4.1 Tablet
  2. 4.4.2 Injection
  3. 4.4.3 Topical
  4. 4.4.4 Liquid
  5. 4.4.5 Capsule
5. 4.5 Healthcare, BY End User (USD Billion)
  1. 4.5.1 Hospitals
  2. 4.5.2 Clinics
  3. 4.5.3 Homecare
  4. 4.5.4 Pharmacies
  5. 4.5.5 Research Institutions
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Sanofi (FR)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bayer (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 GlaxoSmithKline (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck KGaA (DE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Boehringer Ingelheim (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AbbVie (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
  10. 5.2.10 Pfizer (US)
    1. 5.2.10.1 Financial Overview
    2. 5.2.10.2 Products Offered
    3. 5.2.10.3 Key Developments
    4. 5.2.10.4 SWOT Analysis
    5. 5.2.10.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA
3. 6.3 EUROPE MARKET ANALYSIS BY DRUG TYPE
4. 6.4 EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 EUROPE MARKET ANALYSIS BY FORMULATION TYPE
6. 6.6 EUROPE MARKET ANALYSIS BY END USER
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
15. 6.15 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
17. 6.17 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
19. 6.19 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
21. 6.21 HEALTHCARE, BY END USER, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
  2. 7.2.2 BY DRUG TYPE, 2026-2035 (USD Billion)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Billion)
  4. 7.2.4 BY FORMULATION TYPE, 2026-2035 (USD Billion)
  5. 7.2.5 BY END USER, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Europe Healthcare Market Segmentation

Healthcare By Therapeutic Area (USD Billion, 2026-2035)

Cardiovascular
Oncology
Neurology
Diabetes
Infectious Disease

Healthcare By Drug Type (USD Billion, 2026-2035)

Prescription Drug
Over-the-Counter Drug
Biologics
Generics
Orphan Drug

Healthcare By Distribution Channel (USD Billion, 2026-2035)

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Specialty Pharmacy
Wholesalers

Healthcare By Formulation Type (USD Billion, 2026-2035)

Tablet
Injection
Topical
Liquid
Capsule

Healthcare By End User (USD Billion, 2026-2035)

Hospitals
Clinics
Homecare
Pharmacies
Research Institutions

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”